Sensei Biotherapeutics (NASDAQ:FTH) CFO Brian Stephenson Buys 7,803 Shares

Sensei Biotherapeutics, Inc. (NASDAQ:FTH) CFO Brian Stephenson bought 7,803 shares of the business’s stock in a transaction dated Tuesday, June 30th. The shares were acquired at an average cost of $24.25 per share, for a total transaction of $189,222.75. Following the purchase, the chief financial officer owned 41,688 shares of the company’s stock, valued at approximately $1,010,934. The trade was a 23.03% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Sensei Biotherapeutics Trading Down 5.4%

Shares of NASDAQ FTH opened at $23.66 on Thursday. Sensei Biotherapeutics, Inc. has a fifty-two week low of $6.32 and a fifty-two week high of $36.76. The company has a market capitalization of $31.70 million, a PE ratio of -0.17 and a beta of -0.26.

Sensei Biotherapeutics (NASDAQ:FTH) last posted its quarterly earnings data on Friday, May 15th. The company reported ($131.45) earnings per share (EPS) for the quarter. On average, equities research analysts anticipate that Sensei Biotherapeutics, Inc. will post -16.61 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on FTH shares. BTIG Research raised shares of Sensei Biotherapeutics to a “strong-buy” rating in a research note on Thursday, June 11th. HC Wainwright assumed coverage on shares of Sensei Biotherapeutics in a research report on Monday, June 22nd. They issued a “buy” rating and a $60.00 price objective for the company. Robert W. Baird assumed coverage on shares of Sensei Biotherapeutics in a research note on Friday, June 26th. They issued an “outperform” rating and a $57.00 target price on the stock. Finally, Weiss Ratings initiated coverage on shares of Sensei Biotherapeutics in a research note on Wednesday, June 17th. They set a “sell (d-)” rating for the company. Two analysts have rated the stock with a Strong Buy rating, one has given a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Sensei Biotherapeutics currently has a consensus rating of “Buy” and an average target price of $58.50.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing next-generation immunotherapies for cancer. The company applies its proprietary ImmunoPhage platform to create conditionally active biologics designed to stimulate the immune system in the tumor microenvironment while limiting activity in healthy tissue.

Its product pipeline has included experimental therapies such as solnerstotug (formerly SNS-101), a checkpoint inhibitor targeting VISTA, and additional oncology candidates in earlier stages of development.